Interim results of the first two phases of clinical trials of CoviVac vaccine against coronavirus in humans have been summarized. 87% of the study participants, who had no antibodies in their blood before vaccination, were found to have significant quantities of antibodies on day 42 after vaccination. An article describing the tests was published on medRxiv.
“CoviVac vaccine has demonstrated a good level of safety and tolerability. Thanks to vaccination, significant quantities of antibodies appeared in the blood of 86.9% of test participants who had not had a coronavirus infection or had not been vaccinated before the start of the study. Repeated immunization with a single injection of CoviVac led to a more than fourfold increase in the number of antibodies in 85% of cases,” the researchers report.
The tests of CoviVac started in October 2020, with almost 400 volunteers taking part as subjects. Most of them had not had coronavirus before vaccination and had not been vaccinated, but some of the participants were convalescent COVID-19 patients. Thanks to that, the researchers also found out whether it is possible to use the drug for revaccination.
Earlier, it was reported that, according to preliminary data, the effectiveness of CoviVac is about 62%.
The city children’s polyclinic No. 5 in Perm, where the CoviVac vaccine was supposed to be tested on minors, refused to participate in the trials.